Navigation Links
Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement
Date:6/30/2009

LAKE FOREST, Ill., June 30 /PRNewswire-FirstCall/ -- Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical and medication delivery company, today announced agreements with MedAssets on intravenous (I.V.) solutions and gravity I.V. equipment, and a renewal of its agreement for infusion devices. The five-year MedAssets agreements are effective as of June 1, 2009, for I.V. solutions and equipment, and July 1, 2009, for infusion devices. These new agreements represent a first for Hospira from a contract award position on I.V. solutions and gravity I.V. equipment.

"MedAssets shares Hospira's commitment to improving patient and healthcare safety, as well as finding ways to reduce the high costs of healthcare," said Pete Baker, vice president and general manager, Commercial Service Operations, Hospira. "We look forward to continuing our work with MedAssets' member healthcare institutions to drive these goals."

The agreements, all of which run through June 30, 2014, are multi-source awards. They include Hospira's general-purpose medication management technologies, such as the Plum A+(R) device; the next-generation Symbiq(R) infusion system with Hospira MedNet(R) safety software; and pain management pumps, such as the LifeCare PCA(R) device with Hospira MedNet(R) safety software, and GemStar(R) ambulatory devices. These products play a critical role in improving patient safety as well as enhancing quality of care and clinician workflow. Also covered within the agreements is access to contracts for Hospira's I.V. solutions, including the company's environmentally preferable VisIV(R) container, and the IV solutions' associated equipment portfolio.

"We are pleased to expand our relationship with Hospira," said Mark Miriani, president of MedAssets Supply Chain Systems. "Adding Hospira's full line of I.V. solutions and gr
'/>"/>

SOURCE Hospira, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Hospira Receives Favorable Court Decision on Eloxatin(R)
2. Hospira Announces Plans to Integrate Symbiq(R) and EndoTool(R) Technologies
3. Hospira Names Brian Meadows Supply Chain Chief
4. Hospira Supports Newly Introduced Biogenerics Legislation
5. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System
6. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
7. Hospira Hosts Conference Call for Third-Quarter 2008 Earnings
8. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
9. Hospira Expands Board of Directors
10. Hospiras Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval
11. Biogenerics Will Save Billions, Says Hospira CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
(Date:12/17/2014)... --  Synageva BioPharma Corp. (NASDAQ: GEVA ... disorders, announced today its presentation at the upcoming J.P. ... Francisco, CA. Sanj K. ... on Monday, January 12, 2015, at 9:00 a.m. PST ... and may be accessed from the "Webcasts & Presentations" ...
(Date:12/15/2014)... , Dec. 15, 2014  Origin Agritech Limited (NASDAQ ... a technology-focused supplier of crop seeds in China ... for its fiscal year 2014 ended September 30, 2014, before ... The Company will host a teleconference on January 8, 2015, ... time to discuss the results. To participate in ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
... that a new market research report is available in its ... and companies http://www.reportlinker.com/p0203543/Gene-Therapy---technologies-markets-and-companies.html ... on gene therapy with 72 tables and 13 figures ... 700 selected references from the literature - Estimates ...
... Dec. 21, 2010 Exagen Diagnostics, Inc., a specialty ... today announced that it has been awarded $400,000 in ... program, which was created by Congress as part of ...  Proceeds from the grants will be used to advance ...
... Mass. and BRANFORD, Conn., Dec. 20, 2010 ... oncology-focused molecular diagnostics company, and HistoRx, Inc., ... to advance individualized patient care, today announced ... Metamark a worldwide license to the AQUA ...
Cached Biology Technology:Reportlinker Adds Gene Therapy - technologies, markets and companies 2Reportlinker Adds Gene Therapy - technologies, markets and companies 3Reportlinker Adds Gene Therapy - technologies, markets and companies 4Reportlinker Adds Gene Therapy - technologies, markets and companies 5Reportlinker Adds Gene Therapy - technologies, markets and companies 6Reportlinker Adds Gene Therapy - technologies, markets and companies 7Reportlinker Adds Gene Therapy - technologies, markets and companies 8Reportlinker Adds Gene Therapy - technologies, markets and companies 9Reportlinker Adds Gene Therapy - technologies, markets and companies 10Reportlinker Adds Gene Therapy - technologies, markets and companies 11Reportlinker Adds Gene Therapy - technologies, markets and companies 12Reportlinker Adds Gene Therapy - technologies, markets and companies 13Reportlinker Adds Gene Therapy - technologies, markets and companies 14Reportlinker Adds Gene Therapy - technologies, markets and companies 15Reportlinker Adds Gene Therapy - technologies, markets and companies 16Reportlinker Adds Gene Therapy - technologies, markets and companies 17Reportlinker Adds Gene Therapy - technologies, markets and companies 18Reportlinker Adds Gene Therapy - technologies, markets and companies 19Reportlinker Adds Gene Therapy - technologies, markets and companies 20Reportlinker Adds Gene Therapy - technologies, markets and companies 21Exagen Diagnostics Awarded $400,000 in Grants Under the QTDP Program 2Metamark and HistoRx Announce Licensing Agreement for AQUA® Technology 2
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... see the flowers of Edinburgh in full bloom in the depths ... the impact of global warming on spring flowering, published today in ... dating back to the late nineteenth century, has been used to ... further warming will have on plant life by the year 2080. ...
... faster than in any other location on Earth. Researchers at ... indicating that the changes are astonishingly fast. Many original species ... species from southern areas to migrate north, where they occupy ... renowned Science magazine will publish a joint article ...
... ANN ARBOR, Mich.---The growth of cancerous tumors is ... free radicals---highly reactive oxygen-containing molecules. It stands to ... antioxidants, which inhibit the rogue radicals, or with pro-oxidants, ... cancer cells to the point of vanquishing them. ...
Cached Biology News:Early spring time for Edinburgh? Study predicts effect of global warming on spring flowers 2The change in Arctic nature foreshadows the global environment of the future 2New method monitors early sign of oxidative stress in cancer 2